More Stories

Informist, Friday, Jan. 2, 2026

 

MUMBAI – Shares of pharmaceutical companies are likely to move in a range as there are no immediate triggers for the sector. Analysts await the December quarter financial results, which may aid a rise in select pharmaceutical stocks in the coming weeks. According to technical analysts, the Nifty Pharma index has been in a phase of consolidation for the past 15 months and the trend is likely to continue next week. Domestic demand, especially for generic medicines, is expected to be strong on the back of a seasonally strong quarter for generic drug manufacturers.

 

"(The) Nifty Pharma index is still stuck in consolidation," said Anshul Jain, technical analyst at Laxmishree Investments and Securities. The analyst placed the sectoral index's support at 22400 points and expects it to face resistance at 23162 points. For the week ended Friday, the Nifty Pharma index rose 0.5% to end at 22790.90 points. Ajanta Pharma was the outstanding performer, rising nearly 10% in the week. Shares of the company have risen steadily since it signed an in-licensing agreement with Biocon for semaglutide, a glucagon-like peptide-1 receptor agonist that is primarily used to manage type 2 diabetes and for chronic weight management in adults. Dr. Lal Pathlabs and Gland Pharma ended the week 4-5% higher. Caplin Point Laboratories closed the week almost 4% lower. Among Nifty 200 companies, Glenmark Pharma rose nearly 3% in the week.

 

While there are concerns of a loss in market share for insulin products due to the rise in market share of glucagon-like peptide-1 products, Mehul Sheth, analyst at HDFC Securities, said there are no indications to support this argument despite the launch of GLP-1 drugs such as Ozempic and Mounjaro. Among other stocks, analysts are keenly awaiting the financial impact of Lupin's deal with Chinese company Gan & Lee Pharmaceuticals. The company has signed in-India licensing rights for a fortnightly GLP-1 receptor agonist, bofanglutide. 

Analysts are also watching developments around Schedule M implementation. The Union health ministry is in discussions with states to weigh options for giving an extension to implement the revised Schedule M regulations, according to a report by The Economic Times. A six-month extension may be given to select pharmaceutical companies on a case-by-case basis to comply with the rules, the newspaper said, citing sources. Schedule M of the Drugs and Cosmetics Act prescribes good manufacturing practices such as a quick product recall system for products known or suspected to be defective.

 

TOP HEADLINES

* Aurobindo Pharma arm buys Khandelwal Lab's non-oncology ops for INR 3.3 bln
* Caplin Point arms acquire 10 ANDAs for injectable, opthalmic products
* MedPlus Health Services' promoter unpledges 4.2 mln shares
* Dr Reddy's Swiss arm gets US FDA complete response letter for denosumab
* Wockhardt receives fast-track grant for WCK 5222 drug from European agency
* Max Healthcare gets INR 550-mln GST demand on excess input tax credit
* Karnataka High Court passes income tax refund order in favour of Syngene
* Alkem Lab gets balance INR 325 mln for sale of trade generics ops to arm
* Lupin signs exclusive licensing pact with Gan & Lee Pharma for Bofanglutide
* Aurobindo Pharma arm, BioFactura to end pact for Ustekinumab biosimilar
* HC orders removing Ind-Swift Lab Deca-neurophen trademark registration entry
* Sun Pharma targets mid to high single-digit consol topline growth in FY26

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	28,125.00	(-)2.70	28,725.00	27,655.00
Alkem Laboratories	5,592.50	1.00	5,698.50	5,395.50
Aurobindo Pharma	1,215.40	0.80	1,233.80	1,182.80
Biocon	392.95	(-)0.60	399.80	383.00
Cipla	1,511.60	0.40	1,528.50	1,490.10
Divi's Laboratories	6,392.50	(-)0.50	6,439.80	6,308.80
Dr Reddy's Laboratories	1,256.10	(-)1.00	1,271.50	1,228.30
Gland Pharma	1,715.80	3.80	1,745.40	1,669.00
GlaxoSmithKline Pharmaceuticals	2,483.80	0.80	2,515.60	2,428.00
Glenmark Pharmaceuticals	2,064.50	2.70	2,104.80	2,000.80
Granules India	615.35	(-)0.30	630.20	602.80
Ipca Laboratories	1,404.00	(-)2.50	1,425.90	1,382.10
Laurus Labs	1,106.50	2.00	1,121.20	1,095.80
Lupin	2,105.30	(-)0.30	2,134.20	2,081.00
Natco Pharma	893.05	(-)1.70	910.30	878.60
Pfizer	4,887.20	(-)3.30	4,973.90	4,821.70
Sanofi India	4,141.80	1.10	4,187.90	4,065.90
Sun Pharmaceutical Industries	1,728.00	0.50	1,739.10	1,713.90
Torrent Pharmaceuticals	3,885.30	1.80	3,936.00	3,795.60
Zydus Lifesciences	916.90	0.60	922.80	909.10
Nifty Pharma	22790.90	0.50	22949.40	22499.50
Nifty 50	26328.55	1.10	26483.90	26040.70
S&P Bse Sensex	85762.01	0.90	86290.60	84804.60

 

 

End

 

Reported by Eshitva Prakash

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.